» Articles » PMID: 30871264

Computational Approaches in Theranostics: Mining and Predicting Cancer Data

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2019 Mar 16
PMID 30871264
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The ability to understand the complexity of cancer-related data has been prompted by the applications of (1) computer and data sciences, including data mining, predictive analytics, machine learning, and artificial intelligence, and (2) advances in imaging technology and probe development. Computational modelling and simulation are systematic and cost-effective tools able to identify important temporal/spatial patterns (and relationships), characterize distinct molecular features of cancer states, and address other relevant aspects, including tumor detection and heterogeneity, progression and metastasis, and drug resistance. These approaches have provided invaluable insights for improving the experimental design of therapeutic delivery systems and for increasing the translational value of the results obtained from early and preclinical studies. The big question is: Could cancer theranostics be determined and controlled ? This review describes the recent progress in the development of computational models and methods used to facilitate research on the molecular basis of cancer and on the respective diagnosis and optimized treatment, with particular emphasis on the design and optimization of theranostic systems. The current role of computational approaches is providing innovative, incremental, and complementary data-driven solutions for the prediction, simplification, and characterization of cancer and intrinsic mechanisms, and to promote new data-intensive, accurate diagnostics and therapeutics.

Citing Articles

Knockout cancer by nano-delivered immunotherapy using perfusion-aided scaffold-based tumor-on-a-chip.

Suryavanshi P, Bodas D Nanotheranostics. 2024; 8(3):380-400.

PMID: 38751938 PMC: 11093718. DOI: 10.7150/ntno.87818.


Spatiotemporal dissection of tumor microenvironment via in situ sensing and monitoring in tumor-on-a-chip.

Zhou L, Liu L, Chang M, Ma C, Chen W, Chen P Biosens Bioelectron. 2023; 225:115064.

PMID: 36680970 PMC: 9918721. DOI: 10.1016/j.bios.2023.115064.


Advanced Computational Methodologies Used in the Discovery of New Natural Anticancer Compounds.

Chavda V, Ertas Y, Walhekar V, Modh D, Doshi A, Shah N Front Pharmacol. 2021; 12:702611.

PMID: 34483905 PMC: 8416109. DOI: 10.3389/fphar.2021.702611.


Nanomedicine of tyrosine kinase inhibitors.

Smidova V, Michalek P, Goliasova Z, Eckschlager T, Hodek P, Adam V Theranostics. 2021; 11(4):1546-1567.

PMID: 33408767 PMC: 7778595. DOI: 10.7150/thno.48662.


Tumor microenvironment complexity and therapeutic implications at a glance.

Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M Cell Commun Signal. 2020; 18(1):59.

PMID: 32264958 PMC: 7140346. DOI: 10.1186/s12964-020-0530-4.


References
1.
Bertoli G, Cava C, Castiglioni I . MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer. Int J Mol Sci. 2016; 17(3):421. PMC: 4813272. DOI: 10.3390/ijms17030421. View

2.
Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R . Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica. 2013; 98(2):e20-2. PMC: 3561446. DOI: 10.3324/haematol.2012.082404. View

3.
Hasin Y, Seldin M, Lusis A . Multi-omics approaches to disease. Genome Biol. 2017; 18(1):83. PMC: 5418815. DOI: 10.1186/s13059-017-1215-1. View

4.
Bunimovich-Mendrazitsky S, Gluckman J, Chaskalovic J . A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer. J Theor Biol. 2011; 277(1):27-40. DOI: 10.1016/j.jtbi.2011.02.008. View

5.
Villaverde A, Banga J . Reverse engineering and identification in systems biology: strategies, perspectives and challenges. J R Soc Interface. 2013; 11(91):20130505. PMC: 3869153. DOI: 10.1098/rsif.2013.0505. View